JY BioMed ADC Technology Wins Innovation Award, Eyes Global Licensing. Taiwan's JY BioMed has earned the 22nd National Innovation Award for its HCAb-ADC platform, secured FDA Orphan Drug Designation for pancreatic cancer, and published findings in Cancer Letters, as it advances international licensing partnerships across lung, pancreatic, and colorectal cancers.

JY BioMed announces dual FDA Type II Drug Master File acceptance in January 2025, covering UC-MSC and UC-MSC-derived Exosomes. Establishing a fully traceable, vertically integrated regulatory platform, JY BioMed is advancing toward IND submission and positioning as an early leader in the exosome therapeutics space.

JY BioMed Co., Ltd. is proud to announce the publication of its latest research in the internationally renowned journal Cancer Letters, highlighting a novel antibody-drug conjugate (ADC) platform targeting CEACAM6 for the treatment of aggressive cancers, including brain metastases.

Ji Yan Biomedical Co., Ltd. (JY BioMed) today announced that the U.S. Food and Drug Administration (FDA) has completed its review of the Company’s Investigational New Drug (IND) application for Stemis™, an investigational mesenchymal stem cell (MSC) therapy, and has issued a “Study May Proceed” notification. This clearance allows JY BioMed to initiate its Phase 1 clinical trial evaluating Stemis™ in elderly participants with mild to moderate frailty syndrome.

JY BioMed Co., Ltd. (集研生醫股份有限公司) and YC Biotech Co., Ltd. (昱君生技股份有限公司) have jointly submitted a Pre-Investigational New Drug (Pre-IND) Meeting request to the U.S. Food and Drug Administration (FDA) for ExoVeris™, an exosome-based therapeutic candidate, marking another important step forward in the international development of Taiwan’s regenerative medicine sector.

JY BioMed Co., Ltd. (集研生醫股份有限公司) and YC Biotech Co., Ltd. (昱君生技股份有限公司) jointly announced that they have officially submitted a Pre-Investigational New Drug (Pre-IND) Meeting request to the Center for Biologics Evaluation and Research (CBER) of the U.S. Food and Drug Administration (FDA) for Stemis™, a human umbilical cord-derived mesenchymal stem cell (hUC-MSC) therapy.

JY BioMed (Ji Yan Biomedical Co., Ltd.), a biotechnology company focused on next-generation immuno-oncology therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to its investigational therapy, an anti-CEACAM6 humanized heavy chain antibody-drug conjugate (HCAb-ADC), for the treatment of pancreatic cancer.

JY BioMed is pleased to announce that, in collaboration with our clinical development partner YC Biotech, we have officially initiated preparations for a stem cell-based clinical trial targeting Alzheimer’s disease at Taipei Medical University. The trial protocol has been commissioned and is progressing steadily toward regulatory submission and formal IRB review.

JY BioMed today announced that the U.S. Food and Drug Administration (FDA) has granted Investigational New Drug (IND) clearance for its umbilical cord-derived mesenchymal stem cell (UC-MSC) program. The clearance, issued by the Center for Biologics Evaluation and Research (CBER), allows the company to proceed with a first-in-human study under IND number 031083.0.

JY BioMed Co., Ltd. and YC Biotech Co., Ltd. are pleased to announce the formal submission of a regenerative medicine clinical research proposal for Parkinson’s disease to the Joint Institutional Review Board (IRB) of Taipei Medical University and its affiliated hospitals.

JY BioMed announced today the successful submission of a Type II Drug Master File (DMF) to the U.S. Food and Drug Administration (FDA) for its dendritic cell-derived exosome platform. This DMF, assigned Number 041487, provides comprehensive manufacturing and quality control information for investigational use of exosomes obtained from human dendritic cells.

JY BioMed announced today the successful submission of a Type II Drug Master File (DMF) to the U.S. Food and Drug Administration (FDA) for its dendritic cell-derived exosome platform. This DMF, assigned Number 041487, provides comprehensive manufacturing and quality control information for investigational use of exosomes obtained from human dendritic cells.

JY BioMed announced the expansion of its research collaboration with Taipei Medical University (TMU) to investigate the application of gamma delta T cells (γδT) in hepatocellular carcinoma (HCC), the most common form of liver cancer.

JY BioMed today announced the establishment of a targeted research collaboration with Taipei Medical University (TMU) to explore the potential of mesenchymal stem cells (MSCs) in addressing Parkinson’s disease, a leading neurodegenerative disorder worldwide.

JY BioMed announced today the successful submission of a Type II Drug Master File (DMF) to the U.S. Food and Drug Administration (FDA) for its human umbilical cord-derived mesenchymal stem cell (UC-MSC)-derived exosome product. The DMF, assigned Number 041203, documents the manufacturing processes, quality controls, and storage protocols for Ji Yan Biomedical’s investigational exosome platform.

JY BioMed announced today the successful submission of a Type II Drug Master File (DMF) to the U.S. Food and Drug Administration (FDA) for its umbilical cord-derived mesenchymal stem cell (UC-MSC) product. This filing supports the company’s efforts to align with international regulatory standards for cell-based research materials and investigational development.

JY BioMed announced today the submission of a Type II Drug Master File (DMF) to the U.S. Food and Drug Administration (FDA), detailing the manufacturing process, quality controls, and facility compliance for its unmodified gamma delta T cell (Vδ2+ γδT) platform.

JY BioMed announced its active participation in an international biomedical delegation to Japan aimed at fostering cross-border collaboration in regenerative medicine and precision healthcare.

JY BioMed announced the filing of a U.S. Provisional Patent Application for a novel method aimed at the optimized expansion and activation of gamma delta T (γδT) cells for immunotherapy applications.

JY BioMed today announced the initiation of a targeted research collaboration with Taipei Medical University (TMU) to advance preclinical development activities in glioblastoma with its gamma delta T cell (γδT) immunotherapy platform.